Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?
CRISPR Therapeutics (CRSP +1.68%) has had a terrible year, with the stock down 11% as of writing, while the S&P 500 is up 7%. However, the biotech has several catalysts on the horizon, and some analysts are taking notice. Terence Flynn, a Morgan Stanley (MS +3.41%) analyst, recently raised his CRISPR Therapeutics price target to […]